论文部分内容阅读
目的研究巨噬细胞抑制因子-1(MIC-1)在食管癌患者血清中的浓度及其临床应用价值。方法采用双抗体夹心ELISA法检测141例食管癌和3例食管良性疾病患者及200例正常对照人群血清MIC-1浓度,采用电化学发光免疫分析仪检测上述血清标本中CA19-9、CEA浓度。结果食管癌组MIC-1浓度显著高于正常对照组(P<0.001)和良性疾病组;根据ROC曲线,当550 pg/ml作为MIC-1诊断食管癌的临界值时,特异性和敏感性达到最佳,分别为76.7%和82.3%,诊断价值优于CA19-9和CEA;MIC-1浓度随着患者TNM分期的增加而增加,但转移患者(Ⅳ期)MIC-1浓度下降。结论本研究首次确认MIC-1可能成为食管癌新的血清标志物,在食管癌的诊断中,特别是在早期食管癌的诊断方面MIC-1显示出良好的应用前景。
Objective To study the serum concentration of macrophage inhibitory factor-1 (MIC-1) in patients with esophageal cancer and its clinical value. Methods Serum MIC-1 levels in 141 cases of esophageal cancer, 3 cases of esophageal benign disease and 200 cases of normal control were detected by double antibody sandwich ELISA. The concentrations of CA19-9 and CEA in the above serum samples were detected by electrochemiluminescence immunoassay. Results The MIC-1 concentration in esophageal cancer group was significantly higher than that in normal control group (P <0.001) and benign disease group. According to the ROC curve, specificity and sensitivity (76.7% and 82.3%, respectively). The diagnostic value was higher than that of CA19-9 and CEA. The MIC-1 concentration increased with the increase of TNM staging, but the concentration of MIC-1 in metastatic stage (Ⅳ) decreased. Conclusions This study, for the first time, confirms that MIC-1 may be a new serum marker of esophageal cancer. MIC-1 has shown a promising application in the diagnosis of esophageal cancer, especially in the diagnosis of early esophageal cancer.